Cancer remains one of the most pressing public health challenges worldwide, and countries in Central Asia, including Kazakhstan, face growing demand for effective, affordable oncology treatments. Limited local production capacity, high costs of imported innovator drugs, and supply chain complexities often restrict patient access to essential anti-cancer therapies. In this landscape, partnering with a reliable